PKP2-Arrhythmogenic Cardiomyopathy (PKP2-ACM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032


 Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a hereditary cardiac disorder characterized by impaired function of the right ventricle (RV) and the occurrence of ventricular arrhythmias, which can ultimately lead to sudden cardiac death. The condition is characterized by the replacement of cardiomyocytes with fibrofatty tissue. ARVD/C is typically inherited in an autosomal dominant manner, but it exhibits incomplete penetrance, and the expression of the disease varies significantly with age. In rare cases, autosomal recessive inheritance can occur with or without cutaneous involvement. The progressive fibrotic replacement process leads to electrical instability, increasing the risk of syncope and sudden cardiac death, or causing alterations in cardiac function, resembling dilated cardiomyopathy, which may result in right- or bi-ventricular heart failure. The diagnosis of ARVD/C is challenging and relies on applying the 2010 Task Force criteria, which consider family history, distinctive electrocardiographic findings, arrhythmic events, and structural and histological abnormalities. Mutations in the PKP2 gene are responsible for 9-43% of ARVC cases and are considered the most common genetic cause of the condition. However, it should be noted that a single pathogenic variant in PKP2 may not be sufficient to cause the full manifestation of the disease. The PKP2 gene encodes a protein that belongs to the Armadillo (ARM) repeat family. Plakophilin proteins, including Plakophilin-2, contain multiple ARM repeats and are localized in cell desmosomes and nuclei. They play a crucial role in linking cadherins to intermediate filaments in the cytoskeleton. Plakophilin-2 is essential for the assembly of junctional proteins and serves as a vital morphogenic factor and architectural component in the heart. ARVC often exhibits familial clustering, with a family history of the condition present in 30-50% of cases.

·       Additionally, men tend to have a higher incidence and greater severity of ARVC than women. ARVC has an estimated prevalence of 1 per 5000 individuals in the general population

Thelansis’s “PKP2-Arrhythmogenic Cardiomyopathy (PKP2-ACM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential PKP2-Arrhythmogenic Cardiomyopathy (PKP2-ACM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of PKP2-Arrhythmogenic Cardiomyopathy (PKP2-ACM) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

PKP2-Arrhythmogenic Cardiomyopathy (PKP2-ACM) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: PKP2-Arrhythmogenic Cardiomyopathy (PKP2-ACM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more